Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1609||SWOG||DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1612||SWOG||A Randomized Phase II/III Trial of "Novel Therapeutics" versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1613||SWOG||A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1614||SWOG||A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors||Cancer Prevention and Control CIRB||Available to Open|
|S1619||SWOG||A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1701||SWOG||A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1703||SWOG||Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer||Cancer Prevention and Control CIRB||Available to Open|
|S1706||SWOG||A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1712||SWOG||A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1714||SWOG||A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients||Cancer Prevention and Control CIRB||Available to Open|